Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.53 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27348241 | 0.84 | HRH4 (0.41) | DAOPIN1HSD17B10KDM4EHPGD | |
| SCHEMBL26398338 | 0.84 | PLA2G10 (0.42) | DAOPIN1HSD17B10KDM4EGFER | |
| SCHEMBL1244713 | 0.80 | ALDH1A1 (0.54) | HSD17B10KDM4EMAPTHPGDALOX15 | |
| SCHEMBL21632259 | 0.80 | GAA (0.47) | DAOKDM4EMAPTALOX15NPSR1 | |
| SCHEMBL1244709 | 0.78 | DAO (0.53) | DAOPIN1HSD17B10KDM4EMAPT | |
| SCHEMBL1244150 | 0.78 | DAO (0.53) | DAOPIN1HSD17B10KDM4EMAPT | |
| SCHEMBL1244120 | 0.78 | HRH4 (0.56) | DAOHSD17B10KDM4EMAPTHPGD | |
| SCHEMBL23293694 | 0.77 | DAO (0.49) | DAOPIN1HSD17B10KDM4EMAPT | |
| SCHEMBL6053037 | 0.77 | DAO (0.49) | DAOPIN1HSD17B10KDM4EMAPT | |
| SCHEMBL27348080 | 0.77 | TP53 (0.58) | SMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088824-B1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER INC. | 2003-10-16 | — | — | US | claimed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | claimed |
| US-6399601-B1 | ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-06-04 | — | — | US | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| US-20260098047-A1 | Anti-Giardial Compounds | COMMW SCIENT IND RES ORG (AU) | 2026-04-09 | — | — | US | disclosed |
| WO-2025087365-A1 | METTL3 INHIBITOR | 杭州邦顺制药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2024011294-A1 | ANTI-GIARDIAL COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2024-01-18 | — | — | WO | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| EP-2022794-B1 | FLUORESCENT COMPOUND AND LABELING AGENT COMPRISING THE SAME | UNIV KEIO (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010046958-A1 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2001-11-29 | — | — | US | disclosed |
| US-20010046956-A1 | Methods of treating obesity using a neurotensin receptor ligand | HADCOCK JOHN R (US) | 2001-11-29 | — | — | US | disclosed |
| EP-1157695-A1 | Method of treating obesity using a neurotensin receptor ligand | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125580-A2 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, GYS1, PYGM | DAO 1915/4885PIN1 90/4885HSD17B10 212/4885 |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | DAO 841/4885PIN1 2740/4885HSD17B10 632/4885 |
| US-20010046958-A1 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | PYGM, GYS1, PYGL | DAO 1094/4885PIN1 1527/4885HSD17B10 732/4885 |
| US-20260098047-A1 | Anti-Giardial Compounds | GNAO1, GPR6, MGAT3 | DAO 1040/4885PIN1 4754/4885HSD17B10 2925/4885 |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | TSHR, THRA, THRB | DAO 1344/4885PIN1 920/4885HSD17B10 862/4885 |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | CFTR, SLC26A4, PNPO | DAO 841/4885PIN1 2740/4885HSD17B10 632/4885 |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | DAO 1906/4885PIN1 38/4885HSD17B10 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.